menu toggle

Get set for 2025: Mastering the new EU HTA statistical guidelines

By AmerisourceBergen

EU HTA Statistical Guidelines
EU HTA Statistical Guidelines
Don't miss this on-demand webinar featuring Michael Hennig, PhD, Senior Director, Expertise Line Head HTA Statistics at Cencora PharmaLex, and Ruairi O'Donnell, PhD, EU HTA Lead at Cencora, as they shed light on the guidelines for statistical analysis transforming the landscape of European health technology assessment (HTA).  

Scheduled to take effect in January 2025 for oncology and ATMP, these guidelines emphasize evidence synthesis and statistical methods for merging data on study drugs.  

In this interactive session, including a live Q&A with the audience, our experts dive into the intricacies of these guidelines - their evolution, stakeholder involvement, implementation challenges, innovative approaches, adaptability to emerging trends - and discuss their potential impact on decision-making processes within healthcare systems across Europe.  
EU HTA Statistical Guidelines

Watch the webinar now to learn:

  • The importance of evidence synthesis and statistical methods for integrating data on study drugs. 
  • The evolution, stakeholder involvement, implementation challenges, and innovative approaches within the guidelines. 
  • Potential impacts on decision-making processes within healthcare systems across Europe. 
  • Strategies to enhance accuracy and reliability in HTAs through methodological harmonization.
  • Solutions for implementing these new statistical analysis guidelines effectively. 

Fill out the form below to watch the webinar now.

Pardot Form


headshot
Michael Hennig, Ph.D.
Senior Director, Expertise Line Head HTA Statistics, Cencora PharmaLex
headshot
Ruairi O’Donnell, Ph.D.
EU HTA Lead, Cencora
Topics:
Consulting